Malta: Patent Law - Medicinal Products - Specific Provisions

Last Updated: 10 January 2011
Article by Clara Borg

In view of the particular nature of the market for medicinal products, Maltese law provides for specific provisions. The first of which is what is known as the Supplementary Protection Certificate.

Supplementary Protection Certificates (SPCs)

In order for a pharmaceutical/medicinal product to be placed on the market it must obtain what is known as a marketing authorisation. The producer of such product must prove that the product is effective and safe particularly through clinical trials. The process of obtaining such authorisation can take a significant amount of time effectively reducing the actual period of protection for the patent.

Say for example, both a patent and a marketing authorisation are applied for, the patent is granted but the authorisation is only granted 7 years after the patent. This means that the term of protection of the patent is significantly reduced from a full term of 20 years to 13 years.

Therefore, by virtue of Council Regulation (EEC) No 1769/92 'Supplementary Protection Certificates' were introduced, which provided for an extension of the term of up to a maximum of 5 years in cases where both a patent and a marketing authorisation have been granted.

In Malta these provisions are echoed in subsidiary legislation, named Patents (Medicinal Products) Regulations (LN 261 of 2002). By virtue of this Legal Notice an SPC is granted for a period equivalent to the period between the sixth year from filing until the actual date of authorisation, but in all cases for a maximum of 5 years. If the marketing authorisation is granted before the sixth year then there can be no extension. However, if the authorisation is granted after the sixth year then the SPC may be granted for a period equal to the time that has elapsed between the sixth year from filing until the actual marketing authorisation is granted.

Thus for example, if the Patent is granted in 2008 and the marketing authorisation is granted in 2020, then 7 years would have lapsed from the sixth year from filing (2013) until the authorisation is granted in 2020. Therefore the patent term may be extended under an SPC but only up to the maximum period of 5 years. If, the period between the sixth year and the grant of authorisation is less than 5 years then such shorter period would apply.

The second specific provision which applies to medicinal/pharmaceutical products is what is known as the research exemption.

Research Exemption

Manufacturers of generic versions of existing medicinal products may, instead of undergoing extensive trials, refer to the original manufacturer's approval and clinical trials. In order to do so, they must prove that their product is bioequivalent or bio-similar. Therefore, they must carry out studies and tests on their generic product and the reference product (i.e. the already patented product).

Generic manufacturers aim to enter the market immediately upon the expiration of the patented product's term and in order to do so very often they start carrying out tests even before the end of the patent term. The question arises whether such testing before the expiration of the patented term constitutes an infringement of the Patent/SPC.

Roche-Bolar case 1984 & Hatch-Waxman exemption; -

This question was decided in the 1984 US Roche-Bolar case. Bolar was a generics drugs manufacturer and had carried out tests on the product patented under Roche's patent (active ingredient of Valium) prior to the lapse of the patent term, therefore, Roche sued Bolar claiming patent infringement. The law only allowed research for scientific – non-economic purposes. Therefore the Court held that Bolar was in violation of the patent.

Immediately after this decision the Hatch Waxman Act was passed by the US Senate allowing experimentation for the purpose of obtaining FDA Approval. In a more recent case, Merck v. Integra Lifesciences, the US Supreme Court further widened the interpretation of this exemption to include research activities for the development of a new drug.

In Europe, there were no common EU-level provisions in relation to this matter leading to a divergent and inconsistent approach to experimental use across the Member States. This hindered the development of the internal market. Therefore by virtue of Directive 2004/27/EC this exemption was introduced. The Directive provides that:

Conducting the necessary studies and trials with a view to [abridged applications, hybrid applications & bio-similar applications] and the consequential practical requirements shall not be considered as contrary to patent rights or to supplementary protection certificates for medicinal products.

However, it is not as extensive as the US interpretation since it only applies to research in relation to biosimilar/bioequivalent products. These exemptions are also included in our law under the Patents and Designs Act (Chap. 417 of the Laws of Malta). In fact, use for experimental purposes for scientific research (Article 27(6)(b)) and uses reasonably related to the development and submission of information required under any law regulating the manufacture, construction use/sale of medicinal or phytopharmaceutical products (Article 27(6)(d)) are listed amongst those acts which are not considered infringement of a patent under Maltese law.

The research exemption, coupled with a number of business incentives being offered by Malta Enterprise, has attracted foreign investment in the generics pharmaceutical industry since it allows generics pharmaceutical companies to complete all preparatory work on a new product – including production development and licensing – while the branded original is still under patent. They will then be ready to market it immediately when the patent expires, gaining up to a year on manufacturers in countries which do not allow for the research exemption.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions